Next 10 |
home / stock / hrmy / hrmy articles
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Wolf Popper LLP is continuing to investigate potential securities fraud claims on behalf of purchas...
Jeffrey Dierks, Chief Commercial Officer at Harmony Biosciences (NASDAQ:HRMY), reported a large exercise of company stock options on March 18, acco...
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 80% to $6.14 after the company announced it received notice of acceptance from the Australian...
Continued Strong Growth with WAKIX® (pitolisant) Net Revenue of $160.3 Million for Third Quarter 2023; Increased ~37% Year-over-Year Average...
Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) shares are trading higher on Monday as the stock rebounds after falling Friday on Phase 3 INTUNE ...
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 1% on Friday. The Dow traded down 0.02% to 33,...
Gainers Sigma Additive Solutions, Inc. (NASDAQ: SASI) shares jumped 196% to $7.34 after the company announced the signing of a definitive agreeme...
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling over 1% on Friday. The Dow traded down 0.05% to 33,615.27 while ...
Harmony Biosciences Holdings Inc (NASDAQ: HRMY) announced topline results from the INTUNE Phase 3 study of pitolisant in patients with idiopat...
News, Short Squeeze, Breakout and More Instantly...
Harmony Biosciences Holdings Inc. Company Name:
HRMY Stock Symbol:
NASDAQ Market:
HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024 PR Newswire PLYMOUTH MEETING, Pa. , April 16, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2024 f...
HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST TPM-1116 preclinical data suggest a potential best-in-class profile that could transform the treatment of narcolepsy and other sleep/wake...
HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME Trial initiation a step toward potentially treating excessive daytime sleepiness and behavioral symptoms in patients with PWS PR Newswire ...